AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03681106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio Tex
Description: Kinesio Tex tape on the operated limb
Study NCT01337050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03446962
Description: PF 03446962 given by a 1 hour IV infusion. Each patient will initially receive the first dose on Cycle 1 Day 1 with a 28 day observation period. Cycle 2 will start on Day 29. The dosing interval will be 14 days for Cycle 2 and subsequent cycles.
Study NCT00494806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rocking Chair Intervention
Description: Patient out of bed rocking in a rocking chair at a constant rate of one rock cycle per second (back and forth), in ten to twenty minute increments, for at least sixty minutes per day or 3600 rock cycles and ambulate at least twice per day beginning the first postoperative day.
Study NCT02305420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EmbryoGen/ BlastGen media
Description: Embryos will be cultured in media containing Gm-CSF (EmbryoGen/ BlastGen media)
Study NCT02305420 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Cook sequential media
Description: Standard Cook IVF media will be used in the control arm
Study NCT03490682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of gastric emptying of a flavoured yoghourt.
Description: Each participant will be placed on a table, in the semi-recumbent position with elevation of the head at 45° and a first ultrasound examination will be performed. After that, the participant will be invited to eat a test meal (flavoured yoghurt) in 5 minutes. An ultrasound examination of the antrum allowing measurement of the antral area will be performed at 15, 60, 90 and 120 minutes after the end of the ingestion of the test meal. The participant must stay in the semi-recumbent position during the total duration of the study. The non-invasive ultrasound measurement, of the antral cross-sectional area is performed using a Sonosite ultrasound equiped with a 2 -5.5MHz probe. The diameters (longitudinal D1 and anteroposterior D2) of the antrum are measured in the sagittal plane passing by the abdominal aorta and the left lobe of the liver. The value of the antral cross-sectional area is given by the formula : Antral area = π x D1 x D2 / 4.
Study NCT03490682 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound assessment of gastric emptying of a flavoured yoghourt.
Description: Each participant will be placed on a table, in the semi-recumbent position with elevation of the head at 45° and a first ultrasound examination will be performed. After that, the participant will be invited to eat a test meal (flavoured yoghurt) in 5 minutes. An ultrasound examination of the antrum allowing measurement of the antral area will be performed at 15, 60, 90 and 120 minutes after the end of the ingestion of the test meal. The participant must stay in the semi-recumbent position during the total duration of the study. The non-invasive ultrasound measurement, of the antral cross-sectional area is performed using a Sonosite ultrasound equiped with a 2 -5.5MHz probe. The diameters (longitudinal D1 and anteroposterior D2) of the antrum are measured in the sagittal plane passing by the abdominal aorta and the left lobe of the liver. The value of the antral cross-sectional area is given by the formula : Antral area = π x D1 x D2 / 4.
Study NCT03171714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Derma-Stent
Description: The novel device will facilitate self removal by patients, as it has a narrower profile, and, as a nonabsorbent material, will not become saturated with bodily fluids. Although it will not absorb body fluids
Study NCT03171714 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care, cotton gauze packing
Description: Standard gauze packing used to pack a drained abscess.
Study NCT02668302 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Steroid-eluting sinus implant
Description: PROPEL (Intersect ENT, Inc., Menlo Park, CA), containing 370μg of mometasone furoate gradually released over 30 days
Study NCT02668302 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post-op standard of care
Description: Post-op standard of care including debridement, irrigation, and/or topical steroids
Study NCT02668302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-op standard of care
Description: Post-op standard of care including debridement, irrigation, and/or topical steroids
Study NCT01189240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given orally
Study NCT03711708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoloft Oral Solution
Description: Test Product: 50 mg sertraline administered as 2.5 mL of Zoloft Oral Solution (20 mg/mL) after dilution with 120 mL of water
Study NCT03711708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoloft tablets
Description: Reference Product: 50 mg sertraline administered as 1x Zoloft 50 mg tablet
Study NCT01189240 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT02128854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tablets Intervention
Description: The TABLET intervention adds a novel tablet-based delivery mechanism to provide real-time videoconferencing education about diabetes self-management behaviors to high-risk, low-income African American (AA) adults with diabetes. Cardiovascular disease (CVD) knowledge/ information modules consist of materials developed from a CVD patient education booklet adapted from Maine Heart Center of Maine Health and supplemented by clinical guidelines to specifically address behavioral risk factors. Motivation/behavioral skills training modules consist of patient activation (asking questions to providers), patient empowerment (CVD responsibility contracts, flow charts for lab results), and behavioral skills training (self-monitoring, goal-setting).
Study NCT02744729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-3PRGD2
Description: For patients in suspicion of esophagus cancer, single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and thoracic SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.
Study NCT04273529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: 100mg，po，qn，for 14 days.
Study NCT04273529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 100mg，po，qn，for 14 days.
Study NCT04177095 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Allosure
Description: Monthly monitoring of dd-cfDNA levels in blood
Study NCT04177095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppression reduction
Description: Stepwise reduction in the dose, and ultimate discontinuation of, all non-belatacept immunosuppression (mycophenolate, sirolimus, everolimus, prednisone) guided by monitoring of Allosure and Trugraf results
Study NCT04177095 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Trugraf
Description: Monthly monitoring of Trugraf result
Study NCT01024504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin at the dose of 85 mg/m2 over a 4 hour intravenous infusion at day 1 every 2 weeks for a maximum of 12 consecutive cycles
Study NCT01024504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine at the dose of 1500 mg/m2 per os at days 1 to 7 every 2 weeks for a maximum of 12 consecutive cycles
Study NCT01024504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab at the dose of 5 mg/Kgr (intravenous infusion) at day 1, every 2 weeks for a maximum of 12 consecutive cycles
Study NCT01050036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic cell transplantation
Description: 1. Autologous peripheral blood stem cell (PBSCs) harvesting~   * After the second cycle of high-dose ara-C(HDAC) consolidation chemotherapy~  * Mobilization: recombinant human G-CSF(Filgrastim) 5mcg/kg s.c. daily starting on 10 days after start of the second cycle of HDAC chemotherapy~  * Harvest procedure: peripheral blood mononuclear cells will be collected. Target CD34+ cell dose is over 5x10E6/kg.~2. Conditioning regimen for autologous HCT~   * Busulfan 3.2 mg/kg/day i.v. daily on days -7 to -5 (for 3 days)~  * Etoposide 400mg/m2/day i.v. daily on days -3 to -2 (for 2 days)~3. Autologous cell infusion and waiting for engraftment
Study NCT00551239 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: Given IV
Study NCT00551239 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT01189240 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Given IV
Study NCT01189240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01189240 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01189240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01422733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: 10mg/m2/per day PO at bedtime (X12 weeks)
Study NCT01422733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 1 mg PO twice
Study NCT01422733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosyntropin
Description: 250 micrograms IV twice
Study NCT01422733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhCG
Description: 25 mcg IV twice
Study NCT03350022 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Feeding
Description: Sham feeding will be offered to participants.
Study NCT04453566 — intervention group
Intervention type: OTHER
Intervention: Online Survey
Description: Online Survey
Study NCT03419663 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: cereal or grain consumption
Description: intake of cereal, whole grain, refined grain, and other grain of every day
Study NCT00871169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan, oxaliplatin, and cetuximab
Description: Irinotecan at 90 mg/m2 intravenously every two weeks (administered over 60 minutes) + Oxaliplatin at 60 mg/m2 intravenously every two weeks(administered over 60 minutes) + Cetuximab at 250 mg/m2 intravenously every two weeks (administered over 90 minutes).~The treatment interval (one cycle) is every 14 days.
Study NCT02499354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferumoxytol intravenous
Description: IV iron, 2 vials of 510 mg given 2-7 days apart
Study NCT02499354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate
Description: Oral iron, 325 mg tabs taken morning and evening
Study NCT03828461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitated group therapy with behavioral practice; 16 weeks
Description: Facilitated group therapy for hoarding disorder with behavioral practice
Study NCT04179591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Intrinsic foot muscles and tibialis posterior strengthening exercises
Study NCT04179591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orthesis
Description: Customized arch support insoles
Study NCT03035227 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: Catheter ablation of atrial or ventricular arrhythmia. The technique and type of ablation will be at the discretion of the treating electrophysiologists.
Study NCT03035227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Arrhythmics
Description: Anti-Arrhythmic drugs that are deemed to be appropriate for the given participants's arrhythmia by the treating physician.
Study NCT00576199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was supplied as a sterile liquid in single-use vials.
Study NCT00576199 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolisation (TACE)
Description: TACE was conducted by the transfemoral artery approach with selective cannulation of the artery supplying the tumor. Cisplatin mixed with Lipiodol in a 1 mg:1 mL ratio was infused intra-arterially up to a maximum dose of 30 mg, depending on tumor size, followed by embolization of the artery using Gelfoam particle until the blood flow slowed. Bilobar lesions were treated by separate catheterization of right and left hepatic arteries followed by injection of the cisplatin-Lipiodol mixture and embolization.~Patients with stable disease or a partial response after 4 TACE sessions could be given further TACEs upon the investigator's discretion until there was evidence of progressive disease or contraindication due to severe complication or technical failure to perform the TACE.
Study NCT02100956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin 100 micrograms
Description: oxytocin 100 micrograms administered intrathecally (IT)
Study NCT02100956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline (preservative free)
Description: Normal Saline (preservative free) administered intrathecally (IT)
Study NCT03336632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: 20 mg orally, twice weekly from D-7 to D+14
Study NCT03336632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/Kg intravenously D+3, +4
Study NCT03336632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine A
Description: 3 mg/Kg intravenously then orally from D+5 to D+100 if no acute graft-versus-host disease
Study NCT01943461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab 3 mg/kg
Description: Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 3 milligrams per kilogram (mg/kg) once every 2 weeks in the dose- escalation cohort until disease progression, unacceptable toxicity or withdrawal from the study or study drug occurred.
Study NCT01943461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg
Description: Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 10 mg/kg once every 2 weeks in the dose- escalation cohort and expansion cohort until disease progression, unacceptable toxicity or withdrawal from the study or study drug occurred.
Study NCT01943461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab 20 mg/kg
Description: Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 20 mg/kg once every 2 weeks in the dose- escalation cohort until disease progression, unacceptable toxicity or withdrawal from the study or study drug occurred.
Study NCT00943800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG)
Description: Fludarabine is given through the vein daily for 5 days. Melphalan is given through the vein daily for 2 days. ATG is given every day in the vein for four days.
Study NCT00943800 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Infusion of haploidentical donor, umbilical cord blood
Study NCT00943800 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cells Collections
Description: Haploidentical cells will be T-cell depleted using the Miltenyi Clinimax device.
Study NCT00943800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI)
Description: Fludarabine is given through the vein daily for 5 days. Thiotepa is given through the vein daily for 2 days. ATG is given through the vein every other day for 4 days. TBI is given twice a day for 3 days.
Study NCT00943800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine, Busulfan, and ATG
Description: Fludarabine is given through the vein daily for 5 days. Busulfan is given through the vein daily for 4 days. ATG is given through the vein every other day for 4 days.
Study NCT00919958 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PLX-PAD IM injection
Description: Single treatment; multiple injections
Study NCT02655172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive tasks + PANSS+ IQ
Description: Patients will perform different tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield,1971), IQ test (IQ: PM38, Raven, 1960), and the PANSS (Positive and Negative Syndrome Scale (Kay et al., 1987) + the experimental task (affordance task with graspable device)
Study NCT02655172 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cognitive tasks
Description: Healthy volunteers will perform only Edinburgh laterality questionnaire (Oldfield, 1971) + the experimental task (affordance task with graspable device).
Study NCT02311426 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: Function, health related quality of life and rehabilitation needs will be analysed in the two country region groups
Study NCT00521898 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Descemet Membrane Endothelial Keratoplasty (DMEK)
Study NCT03056326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF6333 (Part 1 - SAD)
Description: Single doses of CHF6333 at each period
Study NCT03056326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part 1 - SAD)
Description: Single doses of placebo matching CHF6333 at each period
Study NCT00551239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fludarabine phosphate
Description: Given IV
Study NCT00551239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT00551239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pixantrone dimaleate
Description: Given IV
Study NCT00784329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Frequency Domain Imaging (OFDI) System
Description: Optical Frequency Domain Imaging(OFDI)System. Additional biopsy obtained from regions of normal appearing tissue. Up to an additional 20 minutes to standard Bronchoscopy
Study NCT00634361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethyl-eicosapentaenoic acid
Description: 2 mg per day
Study NCT02779920 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: per oral pylorotomy
Description: The procedure is endoscopic pylorotomy. The standard procedure consists in the realization of a longitudinal incision of 2 cm at the anterior surface of the gastric antrum at 5 cm from the pylorus after a submucosal injection of a solution containing 85% saline 10% glycerol and 5% fructose. This longitudinal incision serve as an input for producing a submucosal tunnel dissected fibers gastric submucosa step. The internal circular of the pyloric muscle is then severed fiber after fiber over its entire length and its entire thickness. Once the pyloric section completed, the tunnel inlet will be closed by means of hemostatic clips.
Study NCT04089631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 6 months capecitabine, in combination with oxaliplatin 3 to 6 months capecitabine
Study NCT01730053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
Study NCT01730053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin over-encapsulated tablets orally.
Study NCT01730053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin over-encapsulated tablets orally.
Study NCT01730053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe over-encapsulated tablets orally.
Study NCT01730053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for alirocumab and ezetimibe.
Study NCT01730053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for alirocumab and ezetimibe.
Study NCT03056326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF6333 (Part 2 - MAD)
Description: once daily multiple doses of CHF6333 for 14 days
Study NCT03056326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part 2 - MAD)
Description: once daily multiple doses of placebo matching CHF6333 for 14 days
Study NCT03016585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi Training
Description: Participants practiced, under supervised instruction, 10 forms from the classic Yang style of Tai Chi 3 times per wk for 12 weeks.The Tai Chi sessions lasted approximately 55 minutes and included a 10-minute warm up, 40 minutes of practice and exercise finalizing with a 5-minute cooldown period.